AUPH — Aurinia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.23bn
- $1.84bn
- $283.06m
Aurinia Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Aurinia's Long Term Phase 3 Data Shows Lupkynis Preserved Kidney Function Up To Three Years
Brief: Market Capital Pleased With Aurinia's Commencement Of A Strategic Review Process
U.S. STOCKS ON THE MOVE-US banks, Circor
U.S. STOCKS ON THE MOVE-Bausch + Lomb, Apple Inc, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Bright Health, Baudax Bio
U.S. STOCKS ON THE MOVE-Aurinia Pharma, Black Diamond Therapeutics, Nvidia
Aurinia Pharma rises on exploring strategic alternatives
Brief: Aurinia Board Of Directors Announces Exploration Of Strategic Alternatives To Maximize Shareholder Value
Brief: Lupkynis® (Voclosporin) Achieved Significantly Higher Renal Response In Lupus Nephritis Patients With High Proteinuria Compared To Patients Treated With Mmf And Low Dose Steroids Alone
Brief: MKT Capital Urges Aurinia Pharma To Commit To Strategic Review Process
Brief: Chin Kyu Huh Says Iljin Snt Co., Ltd. Delivered Letter To Aurinia Pharmaceuticals’ Board
Brief: Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-Study Data From The Lupkynis Aurora 2 Clinical Trial Presented At Congress Of Clinical Rheumatology East Conference
Brief: Market Capital Recommends Aurinia Shareholders Withhold Support For Chairman George Milne At Annual Meeting
Aurinia Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Aurinia Pharmaceuticals Inc - $34.4 Million In Net Revenue For Q1 Of 2023, Up 59%
Brief: Aurinia Pharmaceuticals posts Q1 EPS USD -0.18
Brief: Aurinia Pharmaceuticals Announces Nice Recommendation Of Lupkynis For Adults With Active Lupus Nephritis
Brief: ISS Joins Glass Lewis In Recommending Aurinia Shareholders Vote “For” All Company Director Nominees